Initiation criteria for paediatric acute severe UC
To qualify, a patient (6-17 years) must have:
An infusion of infliximab as a hospital in-patient ≤2 weeks prior to the date of the authority application.
Prior to initiation of infliximab treatment in hospital, patients must have PUCAI ≥65.
Inadequate response† to ≥72 hours treatment with IV corticosteroids prior to initiation of infliximab treatment in hospital.
†Failure to achieve on adequate response to intravenous steroids means a PUCAI score >45 at 72 hours PUCAI, Paediatric Ulcerative Colitis Activity Index
The first infliximab infusion is not subsidised by the PBS, however, second and third infliximab infusions are subsidised for eligible patients. No applications for increased repeats will be authorised.
REMICADE 5mg/kg IV infusion followed by additional 5mg/kg doses at 2 and 6 weeks after the first infusion.
Please refer to Product Information before prescribing. Full product Information is available here. Further information is available on request from Janssen.
PBS INFORMATION: This product is listed as a Section 100 item for Crohn's disease and ulcerative colitis. Refer to PBS Schedule for full authority information.
IRIS number AU-REM0389. Date prepared: November 2014.
Authority is required (HSD 100) and doctors need to call the PBS Authority prescription approval line on 1800 888 333 (available 24 hours a day, 7 days a week) to receive an authority code.
PBS item code: